RAPHAEL PHARMACEUTICAL INC.

As of June 30, 2026, RAPHAEL PHARMACEUTICAL INC. carries a market capitalization of 28.25M, placing it among publicly traded companies globally. Its enterprise value stands at 28.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, RAPHAEL PHARMACEUTICAL INC. has 20.18M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, RAPHAEL PHARMACEUTICAL INC. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2.28, indicating conservative leverage, while an interest coverage ratio of -30.90 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -5,297.30, reflecting losses generated across the asset base.

As of the close on October 16, 2026, RAPHAEL PHARMACEUTICAL INC.'s stock has gained approximately 277.50% over the past 52 weeks.

Over the twelve months ended June 30, 2026, RAPHAEL PHARMACEUTICAL INC. generated - - in revenue and converted that into -980,000.00 in net income, yielding earnings per share of -0.05. EBITDA reached -927,000.00, while operating income came in at -927,000.00.

As of June 30, 2026, RAPHAEL PHARMACEUTICAL INC. holds 1,000.00 in cash and equivalents against 43,000.00 in total debt, resulting in a net debt position of 42,000.00. Total book value stands at -1.88M, with working capital of -1.89M providing operational flexibility.

RAPHAEL PHARMACEUTICAL INC. produced -15,000.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -15,000.00 - equivalent to 0.00 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to RAPHAEL PHARMACEUTICAL INC. shareholders.

As of June 30, 2026, RAPHAEL PHARMACEUTICAL INC. has an Altman Z-Score of -2,875.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.